Plain-English translation of NCT06455293 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a psychedelic compound—combined with professional therapy can help reduce depression in people with Parkinson's disease. Participants will receive the medication in two carefully monitored sessions, with therapy support before and after each session. The study will track changes in mood, quality of life, and Parkinson's symptoms over three months.
Many people with Parkinson's disease experience depression that doesn't respond well to standard antidepressants. This trial explores whether this treatment could offer a new option for people struggling with depression alongside their Parkinson's diagnosis.
You likely qualify if…
You likely don't qualify if…
You would attend two drug administration sessions at UCSF, spaced several weeks apart, where you would receive the medication in a medically supervised setting with a therapist present. Before and after each session, you would participate in therapy visits to prepare for and process the experience. You would also complete clinical assessments, brain imaging, blood tests, and quality-of-life questionnaires at multiple timepoints. The entire study lasts about three months from your first session.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
United States